Jazz Pharmaceuticals plc 8K

Jazz Pharmaceuticals reported strong second quarter 2026 results with record revenues, increased profitability, raised full-year 2026 revenue guidance, and key pipeline and commercial updates across Xywav, Epidiolex, Ziihera, Zepzelca, and Modeyso, supported by solid liquidity and new R&D collaborations.

On August 3, 2026, Jazz Pharmaceuticals plc reported record second quarter 2026 revenues of $1.21 billion, up 16% year-over-year, driven primarily by growth in Xywav, Epidiolex/Epidyolex, Zepzelca, and the addition of Modeyso sales, alongside GAAP net income of $192.8 million and non-GAAP adjusted net income of $396.4 million, and concurrently raised its full‑year 2026 total revenue guidance to a range of $4.60–$4.75 billion. The company highlighted strong commercial performance across sleep, epilepsy, and oncology franchises, including Xywav net sales of $471 million with 525 net patient adds and 17,125 active patients exiting the quarter, Epidiolex/Epidyolex net sales of $292 million (up 16% YoY) with an expanded clinical program and a new NDA for a cannabidiol capsule formulation, Zepzelca net sales of $106 million (up 42% YoY) with plans to remove the second-line SCLC indication via a labeling supplement while maintaining first-line maintenance use, Ziihera net sales of $15 million in biliary tract cancer with preparations for a U.S. launch in HER2+ first-line gastroesophageal adenocarcinoma pending an August 25, 2026 PDUFA date and supported by Phase 3 HERIZON-GEA-01 data and new Breakthrough Therapy designation in HER2+ colorectal cancer, and Modeyso net sales of $48 million with more than 600 patients treated since its August 2025 launch and a Phase 3 ACTION OS interim analysis expected in 1H27. Jazz also disclosed a preclinical research collaboration with AbCellera Biologics to develop next-generation T‑cell engaging multispecific antibodies in GI and other solid tumors, recognized $77 million of acquired in‑process R&D related to AbCellera and Werewolf Therapeutics’ JZP898, reported a strong liquidity position with $2.2 billion in cash, equivalents and investments and repayment of $1.0 billion of 2.00% exchangeable senior notes due 2026, and updated its 2026 GAAP and non‑GAAP guidance, including higher SG&A reflecting increased commercial investment, while reiterating its focus on portfolio expansion, pipeline advancement, and delivering long‑term growth.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

8K

Source Type

fda

Accession

0001232524-26-000044

Alert Tier

6